$KPTI positive results from phase 2/3

Micro cap Karyopharm Therapeutics (KPTI) announced positive results from its Phase 2/3 clinical trial, SEAL, assessing selinexor ((KPT-330)) in patients with previously treated, advanced, unresectable, dedifferentiated liposarcoma.

Read the full brief in our Daily Pharma Scoop at SeekingAlpha Marketplace.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *